165,700 Shares in Solid Biosciences Inc. $SLDB Purchased by Blair William & Co. IL

Key Points

• Blair William & Co. IL purchased 165,700 shares of Solid Biosciences Inc. for approximately $807,000, controlling about 0.21% of the company by the end of the recent quarter.
• Institutional ownership of Solid Biosciences is significant, with 81.46% of the company's stock held by institutional investors as of the latest reporting.
• Solid Biosciences stock currently has an average rating of "Moderate Buy" with a consensus target price of $15.00, despite analysts showing mixed positions on the stock's performance.

Blair William & Co. IL bought a new position in shares of Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 165,700 shares of the company's stock, valued at approximately $807,000. Blair William & Co. IL owned about 0.21% of Solid Biosciences at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SLDB. Adage Capital Partners GP L.L.C. boosted its holdings in Solid Biosciences by 285.0% during the first quarter. Adage Capital Partners GP L.L.C. now owns 6,729,484 shares of the company's stock worth $24,899,000 after buying an additional 4,981,400 shares during the last quarter. Bain Capital Life Sciences Investors LLC boosted its holdings in Solid Biosciences by 96.1% during the first quarter. Bain Capital Life Sciences Investors LLC now owns 7,911,669 shares of the company's stock worth $29,273,000 after buying an additional 3,877,087 shares during the last quarter. Siren L.L.C. boosted its holdings in Solid Biosciences by 97.8% during the first quarter. Siren L.L.C. now owns 7,415,905 shares of the company's stock worth $27,439,000 after buying an additional 3,666,864 shares during the last quarter. MPM Bioimpact LLC bought a new position in Solid Biosciences during the first quarter worth about $6,077,000. Finally, Redmile Group LLC boosted its holdings in Solid Biosciences by 228.2% during the first quarter. Redmile Group LLC now owns 2,019,171 shares of the company's stock worth $7,471,000 after buying an additional 1,403,925 shares during the last quarter. Institutional investors own 81.46% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Wedbush cut their price objective on Solid Biosciences from $17.00 to $14.00 and set an "outperform" rating on the stock in a report on Wednesday, August 13th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Solid Biosciences in a report on Wednesday, October 8th. Wall Street Zen upgraded Solid Biosciences from a "sell" rating to a "hold" rating in a report on Saturday, October 11th. Chardan Capital reissued a "buy" rating and issued a $15.00 target price on shares of Solid Biosciences in a research report on Thursday, August 14th. Finally, Citigroup began coverage on Solid Biosciences in a research report on Thursday, June 26th. They issued a "buy" rating and a $14.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $15.00.

Solid Biosciences Stock Down 2.5%

NASDAQ:SLDB opened at $6.16 on Friday. The firm has a market capitalization of $479.68 million, a price-to-earnings ratio of -2.20 and a beta of 2.53. Solid Biosciences Inc. has a twelve month low of $2.41 and a twelve month high of $7.37. The stock's 50 day moving average price is $5.76 and its two-hundred day moving average price is $4.77.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.42) earnings per share for the quarter, topping analysts' consensus estimates of ($0.51) by $0.09. As a group, analysts anticipate that Solid Biosciences Inc. will post -2.84 earnings per share for the current year.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.

Want to see what other hedge funds are holding SLDB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solid Biosciences Inc. (NASDAQ:SLDB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.